An international multidisciplinary working group of 41 experts systematically reviewed 922 citations up to March 17, 2025, revised the 2016 acute exacerbation (AE) definition—previously limited to idiopathic pulmonary fibrosis (IPF)—into an AE-fILD definition applicable across all fibrotic interstitial lung diseases (anchored in diffuse alveolar damage with or without organizing pneumonia), proposed the broader concept of acute respiratory worsening (ARW) to capture acute deteriorations not attributable to DAD, and summarized evidence on epidemiology, risk factors, prognosis, and management while discussing AE as a clinical trial endpoint.
An international multidisciplinary working group of 41 experts systematically reviewed 922 citations up to March 17, 2025, revised the 2016 acute exacerbation (AE) definition—previously limited to idiopathic pulmonary fibrosis (IPF)—into an AE-fILD definition applicable across all fibrotic interstitial lung diseases (anchored in diffuse alveolar damage with or without organizing pneumonia), proposed the broader concept of acute respiratory worsening (ARW) to capture acute deteriorations not attributable to DAD, and summarized evidence on epidemiology, risk factors, prognosis, and management while discussing AE as a clinical trial endpoint.